Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 4.6%

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) fell 4.6% during trading on Wednesday . The stock traded as low as $23.02 and last traded at $23.02. 52,063 shares changed hands during mid-day trading, a decline of 63% from the average session volume of 141,196 shares. The stock had previously closed at $24.14.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. Wedbush lifted their price target on shares of Dianthus Therapeutics from $24.00 to $33.00 and gave the company an “outperform” rating in a report on Friday, March 22nd. Stifel Nicolaus assumed coverage on shares of Dianthus Therapeutics in a report on Thursday, February 15th. They issued a “buy” rating and a $44.00 price target on the stock. Finally, Jefferies Financial Group lifted their price target on shares of Dianthus Therapeutics from $22.00 to $39.00 and gave the company a “buy” rating in a report on Friday, March 22nd. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Dianthus Therapeutics currently has an average rating of “Buy” and a consensus price target of $37.00.

Dianthus Therapeutics Stock Down 5.1 %

The firm’s fifty day moving average is $25.84 and its two-hundred day moving average is $17.07.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Thursday, March 21st. The company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.40. The business had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.73 million. On average, equities analysts expect that Dianthus Therapeutics, Inc. will post -1.92 EPS for the current year.

Institutional Trading of Dianthus Therapeutics

Hedge funds have recently modified their holdings of the business. Tower Research Capital LLC TRC bought a new stake in shares of Dianthus Therapeutics during the 4th quarter valued at $25,000. Citigroup Inc. bought a new position in Dianthus Therapeutics in the 3rd quarter worth about $53,000. Dimensional Fund Advisors LP bought a new position in Dianthus Therapeutics in the 4th quarter worth about $153,000. Northern Trust Corp bought a new position in Dianthus Therapeutics in the 4th quarter worth about $159,000. Finally, Acadian Asset Management LLC bought a new position in Dianthus Therapeutics in the 3rd quarter worth about $303,000. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.